ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "B-Cell Targets"

  • Abstract Number: 2669 • ACR Convergence 2025

    RESET-Myositis: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), A Fully Human, Autologous 4-1BB CD19-CAR T Cell Therapy in Idiopathic Inflammatory Myopathies

    Erin Wilfong1, Tahseen Mozaffar2, Elie Naddaf3, Nizar Chahin4, Huifang Lu5, Iazsmin Bauer Ventura6, Courtney Little7, Carl diCasoli7, Claire Miller8, Jenell Volkov7, Daniel Nunez7, Thomas Furmanak7, Jason Stadanlick7, Larissa Ishikawa7, Zachary Vorndran7, Alexandra Ellis7, Jazmean Williams7, Steve Flanagan7, Quynh Lam8, Fatemeh Hadi-Nezhad8, Raj Tummala8, Samik Basu7 and David Chang9, 1Vanderbilt University Medical Center, Nashville, TN, USA, Nashville, TN, 2University of California, irvine, Orange, CA, 3Mayo Clinic, Rochester, MN, 4Oregon Health & Science University, Portland, 5UT MD Anderson Cancer Center, Houston, TX, 6University of Chicago, Chicago, IL, 7Cabaletta Bio, Philadelphia, PA, 8Cabaletta Bio, Philadelphia, 9Cabaletta Bio, Bryn Mawr, PA

    Background/Purpose: The goals of treatment for idiopathic inflammatory myopathy (IIM) are to eliminate or reduce inflammation, restore muscle performance, reduce morbidity, and improve a patient’s…
  • Abstract Number: 2293 • ACR Convergence 2025

    CLN-978, a CD19 x CD3-Directed T Cell Engager, Leads to Rapid and Deep B Cell Depletion In Vitro and In Vivo, Supporting Clinical Development Across Multiple Autoimmune Diseases

    Ella Ioffe, Karsten Sauer, Todd Shearer, Jennifer Michaelson, Jeffrey Jones, Yue Zhang, Stephen Wax and Antoine Sreih, Cullinan Therapeutics Inc, Cambridge, MA

    Background/Purpose: Treatments depleting CD19-expressing B cells have shown benefit in a range of autoimmune diseases. T cell engagers (TCE) offer off-the-shelf convenience, the predictable pharmacokinetic/pharmacodynamic…
  • Abstract Number: 1525 • ACR Convergence 2025

    Rituximab super-responders: characteristics of patients with more than 3 years response to a single cycle of treatment

    Md Yuzaiful Md Yusof1, Junaid Patel2, Paul Emery3 and Ed Vital3, 1University of Leeds, Leeds, United Kingdom, 2University of Leeds, Leeds, 3University of Leeds, Leeds, England, United Kingdom

    Background/Purpose: Emerging therapies such as CD19 CAR-T-cells have been reported to induce deeper B-cell depletion and thereby drug-free remission up to 18 months. With rituximab,…
  • Abstract Number: 0908 • ACR Convergence 2025

    E-602 (Efgitasialase alfa) Enhances Memory B Cell Depletion and Reduces Profibrotic Macrophages via Desialylation in Autoimmune Disease

    Hrishikesh Mehta1, Vijayashree Mysore1, Chih-Hsing Chou1, Lizhi Cao1, Rui Liu2, Tianrui Fan2, Jijun Yuan2, James Broderick1 and Li Peng1, 1Palleon Pharmaceuticals, Waltham, MA, 2Shanghai Henlius Biotech, Shanghai, China (People's Republic)

    Background/Purpose: Abnormal cell surface glycosylation has been observed in various autoimmune diseases, including systemic lupus erythematosus (SLE) and membranous nephropathy. Among these glycan modifications, sialoglycans…
  • Abstract Number: 0236 • ACR Convergence 2025

    Safety and Efficacy of T Cell Engager Therapy in patients with refractory Autoimmune Disease

    Laura Bucci1, Sebastian Böltz1, Melanie Hagen1, Danae-Mona Nöthling1, Tobias Rothe2, Carlo Tur1, Andreas Wirsching1, Janina Auth3, jochen wacker1, Markus Eckstein4, Stefano Alivernini5, Aline Bozec1, Christina Bergmann1, Maria Antonietta D'Agostino6, Maria Gabriella Raimondo1, Georg Schett7 and Ricardo Grieshaber-Bouyer8, 1Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, 2Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlagen, Germany, 3Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, 4Institute of Pathology and Comprehensive Cancer Center EMN, Friedrich-Alexander- Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, 5Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, 6Division of Rheumatology and Clinical Immunology - Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, 7Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, 8University Hospital Erlangen, Erlangen, Germany

    Background/Purpose: T cell engagers (TCEs) are a promising therapeutic strategy to treat autoimmune diseases (AID). However, long-term data remain limited.Methods: Patients with treatment-refractory AID were…
  • Abstract Number: 0001 • ACR Convergence 2025

    ATG-201, a Novel Steric Hindrance-based Masking CD19xCD3 T-cell Engager (TCE) for the Treatment of B Cell-related Autoimmune Diseases

    Gang Bian1, Tengteng Li1, Huiling Liu2, Zaoshun Hu2, Peng Chen1, Jay Mei3 and Bing Hou3, 1Shanghai Antengene Corporation Limited, Shanghai, China (People's Republic), 2Antengene (Hangzhou) Biologics, Hangzhou, Zhejiang, China (People's Republic), 3Antengene Corporation, Shanghai, China (People's Republic)

    Background/Purpose: CD19-targeted therapies, such as chimeric antigen receptor (CAR)-T or T-cell engagers (TCE), have been approved for the treatment of B cell malignancies. By depleting…
  • Abstract Number: 2665 • ACR Convergence 2025

    Preexisting Antibodies Against Vaccine Antigens Are Preserved In Patients With Systemic Lupus Erythematosus and Sjögren’s Disease Upon Ianalumab Treatment While Autoantibodies Decline

    Thomas Dörner1, Nan Shen2, Thomas Grader-Beck3, Caroline Walter4, Catherine Wioland4, Celine Rauld4, Patrick Schmutz4, Simone Riek4, Wolfgang Hueber5, CAROLE SIPS6, Stephen Oliver4, Carol Lau7, Claire Bonal6 and Isabelle Isnardi8, 1Charite Universitétsmedizin Berlin, Germany and DRFZ, Berlin, Berlin, Germany, 2Shanghai Jiang Tong University School of Medicine, Shanghai, China (People's Republic), 3Johns Hopkins, Reisterstown, MD, 4Novartis Pharma AG, Basel, Switzerland, 5Novartis Pharmaceuticals, Basel, Switzerland, 6Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland, 7Novartis Pharmaceuticals Corporation, East Hanover, 8Novartis, Gueberschwihr, France

    Background/Purpose: Ianalumab, an afucosylated mAb, depletes B cells via enhanced antibody (Ab)-dependent cellular cytotoxicity and blocks B cell-activating factor (BAFF): BAFF-receptor (BAFF-R) mediated signals.1 It…
  • Abstract Number: 2020 • ACR Convergence 2025

    Inebilizumab Efficacy and Safety in Patients with Common, Urgent, and Fibrotic Organ Manifestations of IgG4-RD: Subgroup Analyses from the MITIGATE Trial

    Arezou Khosroshahi1, Emma Culver2, Wen Zhang3, Kazuichi Okazaki4, Yoshiya Tanaka5, Matthias Lohr6, nicolas schleinitz7, Xinxin Dong8, Sue Cheng8, Daniel Cimbora8 and John Stone9, 1Emory University, Atlanta, GA, 2John Radcliffe Hospital; University of Oxford, Oxford, United Kingdom, 3Peking Union Medical College Hospital, Dong Cheng Qu, China (People's Republic), 4Kansai Medical University Kori Hospital, Osaka, Japan, 5University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 6Karolinska Institutet, Stockholm, Sweden, 7Aix Marseille university, AP-HM, Marseille, France, 8Amgen, Thousand Oaks, CA, 9Massachusetts General Hospital , Harvard Medical School, Concord, MA

    Background/Purpose: IgG4-related disease (IgG4-RD) is a progressive, systemic, fibroinflammatory disease characterized by unpredictable and recurring flares, leading to organ damage and decreased quality of life.…
  • Abstract Number: 1517 • ACR Convergence 2025

    The Chinese Experience with Telitacicept in Lupus Nephritis Management: 51-Patient Cohort Analysis on Therapeutic Outcomes and Safety Parameters

    Aijing Liu1, Fei Chang2 and Qiuhong Xu1, 1Department of Rheumatology and Immunology, The Second Hospital of Hebei Medical University, Shijiazhuang, China (People's Republic), 2Department of Rheumatology and Immunology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China (People's Republic)

    Background/Purpose: Lupus nephritis (LN), affects 30%-50% of systemic lupus erythematosus (SLE) patients, a major contributor to SLE-related mortality. Telitacicept, an innovative recombinant fusion protein, disrupts…
  • Abstract Number: 0907 • ACR Convergence 2025

    Cross-Species Cellular Mapping and Humanization of Fcγ Receptors to Advance Antibody Modeling

    Karel Van Damme1, Dorine Sichien2, Katrien Van der Borght3, Sofie Van Gassen3, Elisabeth De Leeuw3, Victor Bosteels4, Joseph Jorssen5, Seppe De Winter6, Alan Korman7, Fabio Benigni8, Davide Corti8, Ariane Morel9, Eric Vivier9, Hamida Hammad3, Dirk Elewaut10, Fabiane Sonego11, Kader Thiam11, Sofie Voet2, bianca Balbino12 and Bart Lambrecht3, 1Ghent University, Ghent, 2argenx, Ghent, Belgium, 3Ghent University, Ghent, Belgium, 4The Francis Crick Institute, London, United Kingdom, 5Liège Université, Liege, Belgium, 6KU Leuven, Leuven, Belgium, 7Vir Biotechnology, San Francisco, 8Vir Biotechnology, Bellinzona, Switzerland, 9Innate Pharma, Marseille, France, 10VIB Center for Inflammation Research, and Ghent University Hospital, Department of Rheumatology, Ghent, Belgium, 11genOway, Lyon, France, 12argenx, Gent, Belgium

    Background/Purpose: Fc receptors mediate the effector functions of antibodies by linking adaptive and innate immunity. Immunoglobulin G (IgG), the most abundant antibody in circulation and…
  • Abstract Number: 0135 • ACR Convergence 2025

    Rituximab in Antiphospholipid Syndrome: aPL Titer Decline and Clinical Outcomes

    Omer Uludag1, Soner Altın2, Gamze Kemec2, yasemin yalcinkaya3, Ahmet Gul3, Murat Inanc3 and Bahar Artim Esen4, 1Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, 2Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Istanbul, Turkey, 3Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Istanbul, Turkey, 4Istanbul University, Istanbul, Istanbul, Turkey

    Background/Purpose: Rituximab treatment has been shown to be effective in non-thrombotic manifestations of APS and refractory catastrophic APS (CAPS). However, there are conflicting results regarding…
  • Abstract Number: 2641 • ACR Convergence 2025

    Cizutamig, a BCMA T-cell engager: preclinical to clinical translation of design optimization for the treatment of autoimmune diseases

    Ricardo Grieshaber-Bouyer1, Jamie Haddon2, Maria Gabriella Raimondo3, Carlo Tur3, Sebastian Böltz3, Tobias Dashi4, Melanie Hagen5, Andreas Wirsching3, Tobias Rathe4, Xuan Wu6, Peter Wung2, Francis Kim2, Yonghong Zhu6, Ken Song2, Timothy Lu7 and Georg Schett8, 1University Hospital Erlangen, Erlangen, Germany, 2Candid Therapeutics, San Diego, CA, 3Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, 4Department of Internal Medicine 3- Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, 5Friedrich-Alexander-University Erlangen-Nuremberg, Department of Internal Medicine 3 - Rheumatology and Immunology, Erlangen, Germany, 6EpimAb Biotherapeutics, Shanghai, China (People's Republic), 7Candid Therapeutics, San Diego, 8Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany

    Background/Purpose: Emerging data show the potential of T-cell engagers (TCEs) for deep B cell depletion to treat autoimmune diseases. Cizutamig is a purposefully designed BCMAxCD3…
  • Abstract Number: 2019 • ACR Convergence 2025

    Incidence of Coronavirus Disease 2019 in Participants with IgG4-Related Disease Treated with Inebilizumab in the MITIGATE Study

    Arezou Khosroshahi1, Emma Culver2, Wen Zhang3, Kazuichi Okazaki4, Yoshiya Tanaka5, Matthias Lohr6, nicolas schleinitz7, Xinxin Dong8, Sue Cheng8, Daniel Cimbora8 and John Stone9, 1Emory University, Atlanta, GA, 2John Radcliffe Hospital; University of Oxford, Oxford, United Kingdom, 3Peking Union Medical College Hospital, Dong Cheng Qu, China (People's Republic), 4Kansai Medical University Kori Hospital, Osaka, Japan, 5University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 6Karolinska Institutet, Stockholm, Sweden, 7Aix Marseille university, AP-HM, Marseille, France, 8Amgen, Thousand Oaks, CA, 9Massachusetts General Hospital , Harvard Medical School, Concord, MA

    Background/Purpose: The potential of B-cell-depleting therapies to diminish humoral responses is recognized, but whether this leads to an increased risk of Coronavirus Disease 2019 (COVID-19)…
  • Abstract Number: 1198 • ACR Convergence 2025

    Induction of stable, GC-free remission in patients with severe, therapy-refractory anti-synthetase syndrome after using the bispecific CD19xCD3 T cell engager blinatumomab

    Christina Duesing1, Ayla Nadja Stuetz2, Andrea-Hermina Györfi3, Laura-Marie Lahu4, Franca Sophie Deicher5, Gamal Chehab6, Jutta Richter7, Marie Celine van Saan8, Bilgesu Safak Tümerdem2, Alexandru-Emil Matei9, Bjoern Buehring10, Ricardo Grieshaber-Bouyer11, Melanie Hagen12, Georg Schett13, Wolfgang Merkt14 and Jörg Distler15, 1Klinik für Rheumatologie, Düsseldorf, Germany, 2Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Nordrhein-Westfalen, Germany, 3Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University., Düsseldorf, Germany, 4Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Germany, 5Uniklinik Düsseldorf, Düsseldorf, Germany, 6Policlinic of Rheumatology and Hiller Research Unit Rheumatology, Heinrich-Heine-University, Düsseldorf, Germany, 7Clinic for Rheumatology and Hiller Research Unit, Heinrich-Heine-University Duesseldorf, Medical Faculty, Duesseldorf, Germany, Düsseldorf, Germany, 8Department of Rheumatology, University Hospital Duesseldorf, Medical Faculty of Heinrich Heine University, Duesseldorf, 9Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, Germany, Düsseldorf, Germany, 10Bergisches Rheuma-Zentrum, Wuppertal, Germany, 11University Hospital Erlangen, Erlangen, Germany, 12Friedrich-Alexander-University Erlangen-Nuremberg, Department of Internal Medicine 3 - Rheumatology and Immunology, Erlangen, Germany, 13Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, 14University Hospital Düsseldorf, Düsseldorf, Germany, 15University Hospital Duesseldorf and HHU, Duesseldorf, Germany

    Background/Purpose: Treatment of anti-synthetase syndrome (ASyS) presents clinical challenges: myositis can lead to permanent disability and severe organ involvement is life-threatening.Methods: We treated three patients…
  • Abstract Number: 0906 • ACR Convergence 2025

    Preclinical Characterization of IBI3034, an TACI and BCMA Chimeric Fc Fusion Protein, that Potently Modulates B Lymphocytes and Serum Immunoglobulin for the Treatment of B cell Related Autoimmune Disease

    Yao Xiong, Shuaixiang Zhou, Zhimin Zhang, Bin Li, Zhihao Ming, Yuyu Wu, Liu Li, Chang Li, Fenggen Fu, Zhihai Wu, Shun Wang, Guogang Yuan, Yuling Song, Jinyang Li, Huizhong Xiong and Bingliang Chen, Innovent Biologics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China (People's Republic)

    Background/Purpose: Dysregulated B-cell activation plays a pivotal role in the pathogenesis of various autoimmune diseases. B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) are…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 17
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology